Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mg1-magea3
- Development stage
- Phase 2
- Lead developer
- Turnstone Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
MG1-MAGEA3 is a genetically modified oncolytic virus-based cancer vaccine. It consists of the attenuated Maraba virus (MG1 strain) engineered to express the human tumor antigen MAGE-A3. The therapy is designed to selectively infect and lyse cancer cells while simultaneously stimulating an anti-tumor immune response by presenting the MAGE-A3 antigen to the immune system. This dual mechanism aims both for direct oncolysis and for induction of robust cellular and humoral immunity against tumors expressing MAGE-A3. The approach has been evaluated as a single agent or in combination with an adenoviral vector encoding MAGE-A3 (AdMAGEA-3) as a priming step, followed by boosting with MG1-MAGEA-3, sometimes in combination with checkpoint inhibitors such as pembrolizumab[2][6][8]. Developed primarily for advanced/metastatic solid tumors expressing MAGE-A3—including non-small cell lung cancer—the drug has shown immunogenicity and safety in preclinical models and early-phase clinical trials[2][5][6].
- Other names
- Ad MAGEA3 (related prime vaccine)genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine
02
Targets
MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on mg1-magea3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mg1-magea3.